Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X
about
Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivoCell entry and trafficking of human adenovirus bound to blood factor X is determined by the fiber serotype and not hexon:heparan sulfate interactionAdenoviral vectors as novel vaccines for influenza.Defining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction In Vitro in the Presence of Mouse Serum.Hexon hypervariable region-modified adenovirus type 5 (Ad5) vectors display reduced hepatotoxicity but induce T lymphocyte phenotypes similar to Ad5 vectorsInteraction between mouse adenovirus type 1 and cell surface heparan sulfate proteoglycans.Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.Adrenal gland infection by serotype 5 adenovirus requires coagulation factors.Differential effects of murine and human factor X on adenovirus transduction via cell-surface heparan sulfate.Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivoCoagulation factor X mediates adenovirus type 5 liver gene transfer in non-human primates (Microcebus murinus)Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in miceHepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo.Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous deliveryReal-time recording of circadian liver gene expression in freely moving mice reveals the phase-setting behavior of hepatocyte clocks.The relevance of coagulation factor X protection of adenoviruses in human sera.CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter.Innate immunity to adenovirus.An adenovirus traffic update: from receptor engagement to the nuclear pore.Advances and future challenges in adenoviral vector pharmacology and targeting.Manipulation of adenovirus interactions with host factors for gene therapy applications.The importance of coagulation factors binding to adenovirus: historical perspectives and implications for gene delivery.Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls.Tropism-modification strategies for targeted gene delivery using adenoviral vectors.A cluster of basic amino acids in the factor X serine protease mediates surface attachment of adenovirus/FX complexes.New insights into the roles of sulfated glycosaminoglycans in islet amyloid polypeptide amyloidogenesis and cytotoxicity.Biodistribution and inflammatory profiles of novel penton and hexon double-mutant serotype 5 adenoviruses.Coagulation factor IX mediates serotype-specific binding of species A adenoviruses to host cells.Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5.The Intracellular Domain of the Coxsackievirus and Adenovirus Receptor Differentially Influences Adenovirus Entry.Secondary conformational conversion is involved in glycosaminoglycans-mediated cellular uptake of the cationic cell-penetrating peptide PACAP.Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profileFX and host defense evasion tactics by adenovirus.Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.Blood Coagulation Factor X Exerts Differential Effects on Adenovirus Entry into Human Lymphocytes.Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control.Designer Oncolytic Adenovirus: Coming of Age.
P2860
Q28539158-D7C64A7D-B533-4AA3-BF21-2B5DD173F5C6Q28744246-4EA36569-36C2-4D10-B473-2C2CB8464DE8Q30370445-3963DF6A-492D-4202-AC94-878E111B6202Q33440718-036CAA4C-7CB4-4C8E-897F-E5AA68D09D3BQ34057708-1510F17D-328C-47CB-89C7-B535262A54EEQ34162849-F3551989-6015-4D5B-B965-116DE23ED6E7Q34178183-8A6588CB-62EE-4CBA-88B4-27C51156D207Q34701038-3EF77D55-0F72-417C-99FA-75DC3956D329Q35107329-3BDE9E1A-994A-4078-854B-E3F18E3079E3Q35557004-64725C32-429C-4CCF-9C02-70FA008F0B6BQ36055718-F2FED4D3-B24B-403D-811C-7E3C3B668BC2Q36291682-81A7B326-A9EB-4614-8CAE-0B3F9DB2B846Q36433979-C4B87367-7731-47C1-BFA3-B042D2E5C97EQ36445557-D5C30DD3-53FA-4B6C-9E11-885392983467Q37019229-E1979A22-DE95-43AE-BAD3-7B81F732597AQ37085147-43DCD749-FE7C-491D-925A-0C6045AB502EQ37420781-4CF93F8B-9B04-4E6C-B740-8A8AF740DD4DQ37718852-515E3EDC-DA54-4BE0-AFEC-E76B571EF2A0Q37848821-69F662D2-AC88-43FD-BA24-B1655C90C3ADQ37859842-49850139-A9E9-4C24-B29C-DD21B84F5F24Q37984486-575C5042-6B3C-4951-8CBF-7AF932D1932EQ38230901-550C785D-6A17-4781-82AC-963FA7F88DCFQ38295771-82CCF66E-67F1-4767-8968-01C59DB69B2BQ38614156-D9047676-71E3-46E7-BD1D-149E5EBA0EE0Q38631798-94F2F1D2-FF7E-45EE-A6E0-A2CD6A1D7EDAQ39176222-F1981CC4-4CAB-4E2D-BE02-93930C3A30BAQ39342777-C8D19A5A-DE0D-470E-8AD0-0B29F38B9362Q39462577-0962895B-FD07-410F-8AFE-53DE56EBD193Q40103248-CFA2A9F8-2BE6-4106-BEC9-BC0A4336B65DQ40774340-155825F3-FE21-4ED2-95D2-E1B43A525C57Q41758386-FFD2CC5E-94FC-4A0F-B6BF-43E56DBF643CQ41842410-B459A4E0-A567-40B9-B6FC-ED4C60C227D5Q42146790-A448A102-C5C7-4D3F-B938-269194BB171FQ44368424-ED516BCF-0C3D-4481-B577-EBC6338FC163Q47232092-896E2FC3-02B3-4270-8DF7-04256E17C4A3Q47547452-15FCC709-90BF-44E5-94AC-692F669036CBQ55467684-60A3D28E-8235-406E-9643-F81512EE6262
P2860
Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor X
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Requirements for receptor enga ...... ith blood coagulation factor X
@ast
Requirements for receptor enga ...... ith blood coagulation factor X
@en
Requirements for receptor enga ...... ith blood coagulation factor X
@nl
type
label
Requirements for receptor enga ...... ith blood coagulation factor X
@ast
Requirements for receptor enga ...... ith blood coagulation factor X
@en
Requirements for receptor enga ...... ith blood coagulation factor X
@nl
prefLabel
Requirements for receptor enga ...... ith blood coagulation factor X
@ast
Requirements for receptor enga ...... ith blood coagulation factor X
@en
Requirements for receptor enga ...... ith blood coagulation factor X
@nl
P2093
P2860
P50
P3181
P1433
P1476
Requirements for receptor enga ...... ith blood coagulation factor X
@en
P2093
Angela C Bradshaw
Margaret R Duffy
Nico van Rooijen
P2860
P304
P3181
P356
10.1371/JOURNAL.PPAT.1001142
P407
P577
2010-10-07T00:00:00Z